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GH¢205,452.58 (US $141,691.44). CONCLUSIONS: This study showed that average
costs of maternity services were consistently higher at hospitals. The lower health
facilities were under utilized.
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OBJECTIVES: Cost burden of menorrhagia or heavy menstrual bleeding (HMB) has
not been well documented. This study evaluated the healthcare resource utiliza-
tion, work productivity loss, and costs associatedwith newly diagnosed HMB using
a large employer database. METHODS: An analysis was conducted of health in-
surance claims (1998-2009) from 40 self-insured companies across the US.
Women aged 18-52 years with 2 diagnosis claims of HMB (ICD-9: 626.2, 627.0)
within 6 months as of the date of the first HMB diagnosis (“index date”) and
continuously enrolled for 6 months prior to the index date were matched 1:1
with controls (no-HMB) based on exact matching factors and propensity scores.
Exclusion criteria were diagnosis of cancer, pregnancy/delivery, clinician-iden-
tified uterine conditions, endometrial ablation or hysterectomy, diagnosis of
organic causes of HMB, and dispensing of anticoagulant medications. All-cause
healthcare resource utilization and costs were compared between the HMB and
no-HMB control cohorts using statistical methods accounting formatched study
design. RESULTS: The HMB and no-HMB cohorts (31,308 women in each group)
were well-matched with respect to age, year of index date, region, comorbidi-
ties, and baseline costs. During follow-up, HMB patients had significantly higher
all-cause resource utilization than no-HMB patients (hospitalization: incidence
rate ratio [IRR]2.68, 95% CI:2.59-2.76, p.0001; emergency room: IRR1.36, 95%
CI:1.33-1.40, p.0001; outpatient: IRR1.29, 95% CI:1.28-1.29, p.0001]. Average
annualized (per-patient-per-year) all-cause healthcare and work productivity
loss costs were also significantly higher for HMB patients compared to the no-
HMB group ($6,275 vs. $3,740, cost difference$2,535, p.0001). Costs associated
with HMB claims represented 50% ($1,261) of the all-cause cost difference be-
tween the two cohorts. Themost prevalent initial treatment following diagnosis
of HMB was endometrial ablation (45% of patients). CONCLUSIONS: In this large
matched-cohort study, a diagnosis of HMB was associated with significantly
higher healthcare resource utilization and costs.
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OBJECTIVES: Parenteral nutrition (PN) is critical for neonatal care and for infantswho
are unable to tolerate oral or enteral feeding during this important growth period. PN
for these populations is highly complex and involves a multidisciplinary approach.
This study aims to assess the total cost of compounded PN therapy for neonates,
infants, and children.METHODS: A cost-model was constructed to assess total costs
of PN therapy including prescribing, compounding, and administration. This tool was
piloted in 3 Belgian hospitals, with a total of 763 patients and 7,488 compounded bags
annually. Data were collected via literature review and face-to-face interviews in 12
hospitals in4countries (Belgium,France,Germany,andUK)about resource-utilization
and costs. The variable and fixed costs such as ingredients, consumables, equipment,
staff-time were included. Overall costs of hospital PN-therapy were calculated from
expenditures. Staff-time spent preparing PN was measured to determine personnel
costs; bottom-up costing was used to assign a monetary value using published
list-prices. RESULTS: In these hospitals, 93% of all PN bags were compounded in-
hospital (either in the pharmacy or on the ward), and 7% were industrially manufac-
tured. The daily total cost of one bag of in-hospital compounded PN equaled €51.68
(weighted average by PN days) per neonate across all weight groups. Consumables
accounted for 25% of total costs, ingredients 21%, equipment 4% and wages 50%; 22
minutes of staff-timeper PNwasuniquely attributable to compounding, not including
time required for prescribing and supplementation. Average costs per bag using phar-
macy compounding for children2 yrs was €71.47, and for children 2-18 years €71.03,
of which 45% were attributed to ingredients and 35% to wage-costs, respectfully.
CONCLUSIONS: The data showed that a significant proportion of the total cost of PN
wasdue tostaff-time.ReadypreparedPNcould reducestaff-timespentoncompound-
ing for patient-related activities.
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OBJECTIVES: Despite efforts to decrease the incidence of low birth weight (LBW)
and pre-term infants, rates for these conditions have continued to rise in recent
years. The objective of this study was to determine the recent prevalence of and
burden associated with hospitalizations among LBW and pre-term infants in the
United States (US).METHODS: This study used data from the 2008 Healthcare Cost
and Utilization Project Nationwide Inpatient Sample. Hospital stays were selected
for inclusion if the patient was aged 1 year old. Stays were broken into three
categories: LBW/pre-term stays (any diagnosis with an ICD-9-CM code of 764.xx,
765.xx, and V21.3x), uncomplicated newborn stays (primary diagnosis with an ICD-
9-CM code between V30 and V39.2), and all other infant stays. LBW/pre-term stays
were stratified by infants weighing less than or greater than 2,500 grams. Study
measures were weighted and included demographics, hospital characteristics,
length of stay (LOS), and costs. RESULTS: In 2008 there were 499,473 stays for
LBW/pre-term infants, representing 10% of all infant stays. The average LOS for
LBW/pre-term infants was 11.9 days, versus 2.3 days among infants with an un-
complicated newborn stay, and 4.2 days among all other infant stays. LBW/pre-
term infant stays resulted in costs of more than $9.7 billion, or approximately 45%
of all costs for all infant stays, and nearly 1.7 times the costs of uncomplicated
newborn stays. Patients with a birth weight less than 2,500 grams had costs that
were approximately 3.9 times greater than costs for patients with a birth weight
greater than 2,500 grams (mean [SE] $23,382 [$1,220] versus $5,951 [$350] among
patients with a birth weight less than versus greater than 2,500 grams,
respectively). CONCLUSIONS: While LBW/pre-term infant stays represent a small
percentage of all infant hospitalizations, they accrue almost half of all inpatient
costs among infants.
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OBJECTIVES: To evaluate the cost-effectiveness of the LNG-IUS compared with
other therapies for the treatment of heavymenstrual bleeding (HMB) in the United
States (US). METHODS: A microsimulation model examined the five-year treat-
ment experiences of 1,000 hypothetical womenwithHMB fromaUS payer perspec-
tive. Women could begin treatment with LNG-IUS, four oral agents (generic com-
bined oral contraceptives (COCs), branded COCs, oral progestogens, or tranexamic
acid) or surgery (endometrial ablation or hysterectomy). Womenwho failed a non-
surgical treatment line could switch to another non-surgical or surgical therapy (up
to three non-surgical treatment lines were allowed). Women who failed all non-
surgical treatment lines had the option of surgery as a fourth-line treatment. Treat-
ment success was defined as menstrual blood loss  80 milliliters per menstrual
cycle (data were obtained from recent literature). Women could also experience
adverse events, unintended pregnancy, or discontinue treatment during any treat-
ment line (probabilities of these events varied by treatment). Response to treat-
ment was evaluated every three months. The outcome of interest was cost per
hysterectomy avoided. Robustness of model results was tested in Monte Carlo
probabilistic sensitivity analyses. RESULTS: Initiating HMB treatment with LNG-
IUS dominated all other strategies: it was the least costly ($1,253 per woman) and
resulted in fewer hysterectomies (6 per 1,000 women) compared with the other
strategies (costs ranged from$2,291 for generic COCs to $18,219 for hysterectomies;
number of hysterectomies per 1,000 women ranged from 9 for ablation to 96 for
progestogens). Two years of treatment with LNG-IUS was less costly and more
effective than other treatments, except for ablation, which was more costly but
more effective than LGN-IUS. Sensitivity analyses confirmed these results.
CONCLUSIONS: Initiating treatment after five years with LNG-IUS results in fewer
hysterectomies and is a cost-saving, or highly cost-efficient, treatment for HMB
compared with strategies beginning with oral therapies or surgery.
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OBJECTIVES: Over two thirds of women who need contraception in Uganda lack
access to modern effective methods. This study was conducted to estimate the
potential cost-effectiveness of achieving universal access to modern contracep-
tives in Uganda by implementing a hypothetical New Contraceptive Program (NCP)
from both societal and governmental perspectives. METHODS: A Markov model
was developed to compare the NCP to the status quo or Current Contraceptive
Program (CCP). Themodel followed a hypothetical cohort of 15-year old girls over a
lifetime horizon. Data were obtained from the Uganda National Demographic and
Health Survey and frompublished andunpublished sources. Costs, life expectancy,
disability-adjusted life expectancy, pregnancies, fertility and incremental cost-ef-
fectiveness measured as cost per life-year (LY) gained, cost per disability-adjusted
life-year (DALY) averted, cost per pregnancy averted and cost per unit of fertility
reduction were calculated. Univariate and probabilistic sensitivity analyses were
performed to examine the robustness of results. RESULTS: Mean discounted life
expectancy and disability-adjusted life expectancy (DALE) were higher under the
NCP vs. CCP (28.74 vs. 28.65 years and 27.38 vs. 27.01 respectively). Mean pregnan-
cies and live births perwomanwere lower for theNCP (9.51 vs. 7.90 and 6.92 vs. 5.79
respectively). Mean lifetime societal costs perwomanwere higher for theNCP from
the societal perspective ($1,074 vs. $1,041) and the governmental perspective ($448
vs. $397). The incremental cost-effectiveness ratio comparing the NCP to the CCP
was $88 per DALY averted (societal perspective) and $138 per DALY averted (gov-
ernmental perspective). The results were robust to univariate and probabilistic
sensitivity analysis. CONCLUSIONS: Universal access to modern contraceptives in
Uganda appears to be highly cost-effective. Increasing contraceptive coverage
should be considered among Uganda’s public health priorities.
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